Premenopausal women who were assigned to follow the Atkins diet for one year lost more weight and improved their glucose, lipids and blood pressure, when compared to women who were assigned to follow the Zone, Ornish and LEARN diets, according to a study in the March 7 issue of JAMA.
For a more detailed explanation of the study, see this weeks Feature: Low Carb Diets Vindicated
"Concerns about adverse metabolic effects of the Atkins diet were not substantiated within the 12-month study period with over 300 overweight women.
Overweight and obesity are well-documented problems in the United States. National dietary weight loss guidelines (a diet low in calories and fat, high in carbohydrates) have been challenged, particularly by supporters of low-carbohydrate diets. However, limited evidence has been available to effectively evaluate other diets, according to background information in the article.
Christopher D. Gardner, Ph.D., of Stanford University Medical School, Stanford, Calif., and colleagues examined the effects of four diets-3 popular and substantially different diets and 1 diet based on national guidelines-representing a spectrum of carbohydrate intake, on weight loss and related metabolic variables in overweight and obese premenopausal women. The diets were Atkins (very low in carbohydrate), Zone (low in carbohydrate), LEARN (Lifestyle, Exercise, Attitudes, Relationships, and Nutrition; low in fat, high in carbohydrate, based on national guidelines), and Ornish (high in carbohydrate). The study, which included 311 overweight/obese (body mass index, 27-40) nondiabetic, premenopausal women, was conducted from February 2003 to October 2005. Participants were randomly assigned to follow for 12 months the Atkins (n = 77), Zone (n = 79), LEARN (n = 79), or Ornish (n = 76) diets and received weekly instruction for 2 months, then an additional 10-month follow-up.
Besides weight loss, the participants were also measured for lipid profile (low-density lipoprotein, high-density lipoprotein, and non-high-density lipoprotein cholesterol, and triglyceride levels), percentage of body fat, waist-hip ratio, fasting insulin and glucose levels, and blood pressure. Outcomes were assessed at months 0, 2, 6, and 12.
The researchers found that weight loss was greater for women in the Atkins diet group compared with the other diet groups at one year. Average 12-month weight loss was 10.4 lbs for Atkins, 3.5 lbs. for Zone, 5.7 lbs. for LEARN, and 4.8 lbs. for Ornish. At 12 months, measurements for lipids and levels of insulin, glucose and blood pressure for the Atkins group were comparable with or more favorable than the other diet groups.
"Concerns about adverse metabolic effects of the Atkins diet were not substantiated within the 12-month study period. It could not be determined whether the benefits were attributable specifically to the low carbohydrate intake vs. other aspects of the diet (e.g., high protein intake). While questions remain about long-term effects and mechanisms, these findings have important implications for clinical practice and health care policy. Physicians whose patients initiate a low-carbohydrate diet can be reassured that weight loss is likely to be at least as large as for any other dietary pattern and that the lipid effects are unlikely to be of immediate concern. As with any diet, physicians should caution patients that long-term success requires permanent alterations in energy intake and energy expenditure, regardless of macronutrient content," the authors conclude.
Breaking News from the American Diabetes Association 66th Scientific Sessions
Did you miss the ADA Scientific Sessions in Washington, DC? Get up to speed on the latest research and updates to current knowledge on diabetes and dyslipidemia-FREE CME Activities from the ADA Scientific Sessions are now available! Click here to access the interactive CME newsletter summary of several presentations relevant to clinical practice and the CME case-based slide and audio presentations on the real-world management of patients with diabetes and dyslipidemia recorded at the ADA meeting. Don’t miss this opportunity to learn the latest clinical updates from one of the year’s most critical diabetes events!